Skip to main content
Premium Trial:

Request an Annual Quote

Seeking Nasdaq Listing, WaferGen Effects One-for-10 Reverse Stock Split

NEW YORK (GenomeWeb) – WaferGen Biosystems said after the close of the market on Monday that it has effected a one-for-10 reverse stock split as it seeks to list its shares on the Nasdaq Capital Market.

The company's shares will start trading on a split adjusted basis on the OTCBB when the markets open on July 1. The shares will trade for 20 days under the temporary trading symbol "WGBSD." The "D" indicates that the reverse stock split has occurred.

As a result of the reverse stock split, the number of WaferGen's issued and outstanding shares will contract to about 930,000 shares from 9.3 million shares. Earlier this month, the Fremont, Calif.-based firm disclosed its intentions to move to the Nasdaq following a $40 million public offering of its common stock.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.